![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
https://www.inke.es/news/neuraxpharm-agrees-on-the-divestment-of-inhalation-api-specialist-inke-to-keensight-capital-3/
https://www.inke.es/news/inke-increases-its-production-capacity-with-the-support-of-accio-generalitat-de-catalunya-5/
https://iberianlawyer.com/clifford-chance-advises-on-the-financing-for-keensight-capitals-acquisition-of-inke/?print-posts=pdf#:~:text=Clifford%20Chance%20has%20advised%20Eurazeo,to%20the%20Neuraxpharm%20pharmaceutical%20group.
https://www.prnewswire.com/news-releases/neuraxpharm-announces-closing-of-acquisition-of-established-products-from-sanofi-301735596.html
https://www.prnewswire.com/news-releases/neuraxpharm-completes-its-presence-in-benelux-by-opening-an-affiliate-in-brussels-to-cover-belgium-and-luxembourg-301728349.html
https://www.prnewswire.com/news-releases/neuraxpharm-launches-european-campaign-to-increase-awareness-of-medical-cannabis-301652618.html
https://www.prnewswire.com/news-releases/neuraxpharm-to-increase-branded-business-through-upcoming-acquisition-of-established-products-from-sanofi-301584467.html
https://www.inke.es/leading-inhalation-apis-expert-inke-to-triple-production-capacity-n-85-en
https://www.prnewswire.com/news-releases/leading-inhalation-apis-expert-inke-to-triple-production-capacity-301528741.html
https://www.prnewswire.com/news-releases/panaxia-and-neuraxpharm-first-export-of-medical-cannabis-sublingual-tablets-to-france-301466357.html